Ertugliflozin meets in Phase III diabetes studies

Merck & Co. Inc. (NYSE:MRK) and Pfizer Inc. (NYSE:PFE) said diabetes candidate ertugliflozin ( PF-4971729, MK-8835) met the primary endpoints in two Phase III studies. The partners plan to submit an NDA for the oral sodium-glucose cotransporter 2 (

Read the full 398 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE